相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials
Stanley B. Cohen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Juvenile Idiopathic Arthritis: Diagnosis and Treatment
Gabriella Giancane et al.
RHEUMATOLOGY AND THERAPY (2016)
Prevalence and incidence of juvenile idiopathic arthritis: A systematic review
Sigrid Thierry et al.
JOINT BONE SPINE (2014)
The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Tofacitinib, a Janus Kinase Inhibitor, in Humans
Martin E. Dowty et al.
DRUG METABOLISM AND DISPOSITION (2014)
2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among Children Receiving Biologic Medications
Sarah Ringold et al.
ARTHRITIS AND RHEUMATISM (2013)
Incidence and Prevalence of Juvenile Idiopathic Arthritis Among Children in a Managed Care Population, 1996-2009
Leslie R. Harrold et al.
JOURNAL OF RHEUMATOLOGY (2013)
A Phase IIb Dose-Ranging Study of the Oral JAK Inhibitor Tofacitinib (CP-690,550) Versus Placebo in Combination With Background Methotrexate in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone
Joel M. Kremer et al.
ARTHRITIS AND RHEUMATISM (2012)
Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis
Fabrizio De Benedetti et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Networking in paediatrics: the example of the Paediatric Rheumatology International Trials Organisation (PRINTO)
Nicolino Ruperto et al.
ARCHIVES OF DISEASE IN CHILDHOOD (2011)
2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Initiation and Safety Monitoring of Therapeutic Agents for the Treatment of Arthritis and Systemic Features
Timothy Beukelman et al.
ARTHRITIS CARE & RESEARCH (2011)
Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment
Stanley Cohen et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Effect of CP-690,550, an Orally Active Janus Kinase Inhibitor, on Renal Function in Healthy Adult Volunteers
Nervin Lawendy et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Abatacept in children with juvenile idiopathic arthritis:: a randomised, double-blind, placebo-controlled withdrawal trial
Nicolino Ruperto et al.
LANCET (2008)
Adalimumab with or without methotrexate in juvenile rheumatoid arthritis
Daniel J. Lovell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Exposure-response modeling using latent variables for the efficacy of a JAK3 inhibitor administered to rheumatoid arthritis patients
Matthew M. Hutmacher et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2008)
A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis
Nicolino Ruperto et al.
ARTHRITIS AND RHEUMATISM (2007)
Juvenile idiopathic arthritis
Angelo Ravelli et al.
LANCET (2007)
分享论文
